Connecting SNAP Benefits to Health in Delaware

In recent years, numerous states have pursued or received waivers from the U.S. Department of Agriculture (USDA) to limit certain food and beverage purchases with Supplemental Nutrition Assistance Program (SNAP) benefits. These waivers, set to take effect in 2026, allow states to restrict the use of SNAP benefits for products like soda and other sugar-sweetened beverages, which are often linked to obesity and related health conditions. However, Delaware has chosen not to seek such waivers, and this decision invites a broader question: Should public nutrition assistance policies be better aligned with health policies, especially in the face of rising obesity rates?

The Health Impact in Delaware

Obesity has become a pressing issue in Delaware, with nearly 38% of adults reporting obesity in 2022, according to the Delaware Department of Health and Social Services (DHSS). Furthermore, nearly 24% of adults with obesity also reported having diabetes, compared to just 5.3% of adults with a normal weight. These statistics reflect the significant health risks associated with obesity, including Type 2 diabetes, high blood pressure, heart disease, and stroke, as highlighted by the National Institute of Diabetes and Digestive and Kidney Diseases.

The health risks associated with obesity begin early, with concerning trends seen among Delaware’s youth. A 2021 survey from DHSS revealed that 15% of Delaware high school students reported being obese, while nearly one-third were classified as overweight or obese. The survey also found widespread consumption of sugar-sweetened beverages, low intake of fruits and vegetables, and insufficient physical activity among adolescents—habits that often carry over into adulthood, contributing to chronic diseases and rising healthcare costs.

Obesity Treatment and GLP-1 Medications

As the rates of obesity and its related diseases rise, so does the use of medical treatments to address these issues. One such treatment gaining attention is the class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists, which includes drugs like semaglutide. GLP-1 medications are prescribed for both obesity and Type 2 diabetes, acting on appetite regulation and glucose metabolism. Large randomized clinical trials published in The New England Journal of Medicine have shown that these medications can result in sustained weight loss and improvements in metabolic health.

In Delaware, the use of GLP-1 medications has surged in recent years, with the Delaware Department of Insurance noting a significant increase in their utilization. The state already allows Medicaid coverage for these medications under specific clinical criteria. However, these medications now account for more than 6% of total pharmacy spending in the fully insured market, which raises questions about balancing access with affordability.

Bridging the Gap: Aligning SNAP with Medical Treatment

While SNAP and Medicaid are both crucial public assistance programs, they operate independently. SNAP influences dietary behavior, while Medicaid often bears the cost of treating obesity and related diseases. Nutrition assistance policies continue to allow the purchase of sugar-sweetened beverages with SNAP benefits, even though these items are identified as significant contributors to obesity, especially among youth. The overlap between these two programs presents a unique opportunity to better align public policy for improved health outcomes.

The current separation of these two programs represents a missed opportunity to improve long-term health and reduce healthcare costs. A more coordinated approach would not require new taxes or expanded eligibility. Instead, it would give individuals the option to use existing public benefits in ways that more effectively address obesity prevention and treatment.

By integrating SNAP with obesity treatment programs like GLP-1 medications, Delaware could potentially reduce future health risks and lower the cost burden on the healthcare system. For example, linking SNAP benefits to medically prescribed nutrition support could help recipients make healthier food choices that complement their obesity treatment plans.

A Path Forward: Seizing the Opportunity for Healthier, More Sustainable Public Assistance

Delaware’s decision to forgo SNAP restrictions, including those on sugar-sweetened beverages, signals the importance of considering alternative approaches to public health. Rather than limiting food choices, Delaware could seize this moment to pilot a coordinated SNAP and Medicaid strategy that supports healthier lifestyles and long-term health outcomes. By doing so, the state could improve the sustainability of its public assistance programs and reduce the long-term costs associated with obesity and related diseases.

Delaware has an opportunity to lead the way in developing a more integrated, health-conscious approach to public assistance—one that empowers individuals to make better dietary choices while also addressing the medical needs of those struggling with obesity. Source